Search

Your search keyword '"Sastre Garriga, Jaume"' showing total 792 results

Search Constraints

Start Over You searched for: Author "Sastre Garriga, Jaume" Remove constraint Author: "Sastre Garriga, Jaume"
792 results on '"Sastre Garriga, Jaume"'

Search Results

1. The influence of MOGAD on diagnosis of multiple sclerosis using MRI

4. Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study

8. Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS)

9. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI

12. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

13. The ageing central nervous system in multiple sclerosis: the imaging perspective.

15. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

17. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab

18. Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

19. Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs

20. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

23. Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI.

24. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

26. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria

27. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis

29. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.

30. T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.

31. CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis

32. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

33. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

34. MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis

35. The hippocampus in multiple sclerosis

36. The role of the cerebellum in multiple sclerosis—150 years after Charcot

37. Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

38. Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials

41. Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study

42. Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

43. Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials

44. Prognostic value of single-subject grey matter networks in early multiple sclerosis

46. Association of Very Early Treatment Initiation With the Risk of Long-Term Disability in Patients With a First Demyelinating Event

47. Corrigendum to “Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis” [Journal of the Neurological Sciences 449C (2023) Start page–End page/JOTNS D-23-00048R2]

48. Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes

50. Prognostic value of single-subject grey matter networks in early multiple sclerosis.

Catalog

Books, media, physical & digital resources